|Bid||76.20 x 0|
|Ask||80.10 x 0|
|Day's range||77.80 - 78.70|
|52-week range||40.80 - 79.90|
|Beta (5Y monthly)||1.43|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||18 May 2016|
|1y target est||N/A|
ProtOnART builds upon the partners' long-standing research efforts and shared ambition that an online adaptive workflow has the potential to significantly increase the quality of cancer treatments by making better use of the conformal nature of proton radiation. Thereby, the healthy tissue-sparing dose distribution of protons will be secured along the treatment course by continuously adapting the treatment to anatomical changes or inter and even intra-fractional motion.
RaySearch issues a correction of the press release that was sent out at 4 pm CEST on June 3, 2022. The correction refers to the fact that the date of sale of shares should have been May 31, 2022.